Prime Medicine (PRME) Enterprise Value (2022 - 2026)

Prime Medicine (PRME) has 6 years of Enterprise Value data on file, last reported at -$135.5 million in Q1 2026.

• Quarterly Enterprise Value fell 41.45% year-over-year to -$135.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$135.5 million (down 41.45% YoY) and the FY2025 annual result came in at -$177.7 million, up 4.2% from the prior year.
• Enterprise Value advanced to -$135.5 million in Q1 2026, from -$177.7 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$47.0 million in Q4 2023 to a low of -$286.1 million in Q4 2022.
• A 5-year average of -$132.7 million and a median of -$127.0 million in 2023 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2023 — Enterprise Value surged 83.56% — and 2024, when it plunged 294.41%.
• Tracing PRME's Enterprise Value over 5 years: stood at -$286.1 million in 2022, then soared by 83.56% to -$47.0 million in 2023, then sank by 294.41% to -$185.5 million in 2024, then climbed by 4.2% to -$177.7 million in 2025, then climbed by 23.74% to -$135.5 million in 2026.
• The last three Enterprise Value figures came in at -$135.5 million (Q1 2026), -$177.7 million (Q4 2025), and -$76.3 million (Q3 2025), per Business Quant data.